Suven Pharmaceuticals on Monday said its consolidated profit after tax has increased by 11 per cent to Rs 92 crore for the fourth quarter ended March.
The company had reported a profit after tax (PAT) of Rs 83 crore in the January-March quarter of 2020-21 fiscal.
Revenue from operations rose to Rs 364 crore in the fourth quarter as against Rs 259 crore in the same period of previous fiscal, Suven Pharmaceuticals said in a regulatory filing.
For the year ended March 31, 2022, the drug firm reported a PAT of Rs 454 crore as compared with Rs 362 crore in FY21.
Revenue from operations rose to Rs 1,320 crore as against Rs 1,010 crore in the 2020-21 financial year.
The Hyderabad-based company said its board has approved second interim dividend of Re 1 per share (100 per cent) and a one-time special dividend of Re 1 per share, totalling to Rs 2 for the financial year 2021-22. PTI MSS MSS AJ AJ
To stay updated with the Latest Stock Market news, download our app here!
For editorial purposes, contact news@tradebrains.in
Disclaimer: The Stocks mentioned on this website or any segment are not recommendations. Tradebrains.in advises users to check with certified experts before taking any investment decisions.
